- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02516150
Effect of Ethanol Intoxication on the Anti-Hypoglycemic Action of Glucagon
July 31, 2017 updated by: Steven J. Russell, MD, PhD, Massachusetts General Hospital
Effect of Ethanol Intoxication on the Anti-hypoglycemic Action of Glucagon
This study will test the hypothesis that a BAC (blood alcohol content) of 0.1% will not significantly alter the anti-hypoglycemic effect of mico-dose glucagon in individuals with type 1 diabetes.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study will test the hypothesis that a BAC (blood alcohol content) of 0.1% will not significantly alter the anti-hypoglycemic effect of mico-dose glucagon in individuals with type 1 diabetes.
The study will aim to quantify the effect of a blood alcohol content on the anti-hypoglycemic efficacy of glucagon using a hyperinsulinemic -normoglycemic clamp technique in volunteers with type 1 diabetes in a randomized crossover trial.
Study Type
Interventional
Enrollment (Actual)
26
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital Diabetes Research Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 21 to 80 years old with type 1 diabetes for at least one year.
- Diabetes managed using an insulin infusion pump using rapid-acting insulin such as insulin aspart (NovoLog), insulin lispro (Humalog), or insulin glulisine (Apidra) for at least one week prior to enrollment.
- Alcohol exposure on at least one occasion in the last year consisting of at least 4 drinks in one sitting.
Exclusion Criteria:
- Unable to provide informed consent.
- Unable to comply with study procedures.
- Unable to refrain from the consumption of alcohol at least 24 hours prior to study start.
- Current participation in another diabetes-related clinical trial that, in the judgment of the principle investigator, will compromise the results of the clamp study or the safety of the subject.
- Pregnancy (positive urine HCG), breast feeding, plan to become pregnant in the immediate future, or sexually active without use of contraception.
- Aldehyde dehydrogenase deficiency as determined by a screening questionnaire
- End stage renal disease on dialysis (hemodialysis or peritoneal dialysis).
- History of pheochromocytoma (because glucagon has been reported to precipitate hypertensive crisis in the setting of pheochromocytoma). Fractionated metanephrines will be tested in patients with a history increasing the risk for a catecholamine secreting tumor:
- Paroxysms of tachycardia, pallor, or headache. Personal or family history of MEN 2A, MEN 2B, neurofibromatosis, or von Hippel-Lindau disease, Episodic or treatment of refractory (requiring 4 or more medications to achieve normotension) hypertension.
- History of adverse reaction to glucagon (including allergy) besides nausea, vomiting, or headache.
- Inadequate venous access as determined by study nurse or physician at time of screening.
- Liver failure or cirrhosis
- Hemoglobin < 12 gm/dl.
- History of problem drinking or alcoholism, regardless of whether active or in remission.
- Use of benzodiazepines or barbiturates or opiates or other central nervous system depressant drugs that could act synergistically with ethanol to lower the level of consciousness
- Any other factors that, in the judgment of the principal investigator, would interfere with the safe completion of the study procedures.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Glucagon with Ethanol
Volunteers will receive an infusion of IV ethanol that will increase their BAC (blood alcohol content) to 0.1.
Once their BAC has stabilized at 0.1%, 50 micrograms of glucagon will be administered via subcutaneous injection.
|
IV infusion of ethanol to stabilize BAC (blood alcohol content) at 0.1%
Other Names:
injection of 50 micrograms of glucagon
|
Active Comparator: Glucagon without Ethanol
Volunteers will not receive an infusion of IV ethanol at this visit.
50 micrograms of glucagon will be administered via subcutaneous injection.
|
injection of 50 micrograms of glucagon
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AOCGIR (Area Over the Curve for Glucose Infusion Rate)
Time Frame: 1 Day Visit (approximately 8 to 11 hours)
|
Area over the curve for the glucose infusion rate in the hour following a subcutaneous glucagon dose with a blood alcohol content of 0 vs 0.1%
|
1 Day Visit (approximately 8 to 11 hours)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Change in GIR (Glucose Infusion Rate) From Baseline
Time Frame: 1 Day Visit (approximately 8 to 11 hours)
|
This outcome is measuring the maximum change in the glucose infusion rate from the GIR at the time of the injection through the 90 minutes after the glucagon injection in the presence and absence of ethanol.
The glucose infusion rate is adjusted up to every two minutes throughout the clamp, and for 90 minutes total after the glucagon injection.
|
1 Day Visit (approximately 8 to 11 hours)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2016
Primary Completion (Actual)
May 1, 2017
Study Completion (Actual)
June 1, 2017
Study Registration Dates
First Submitted
July 28, 2015
First Submitted That Met QC Criteria
August 3, 2015
First Posted (Estimate)
August 5, 2015
Study Record Updates
Last Update Posted (Actual)
August 31, 2017
Last Update Submitted That Met QC Criteria
July 31, 2017
Last Verified
July 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Immune System Diseases
- Autoimmune Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Physiological Effects of Drugs
- Anti-Infective Agents, Local
- Anti-Infective Agents
- Central Nervous System Depressants
- Gastrointestinal Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Ethanol
- Glucagon
Other Study ID Numbers
- 2015P001323
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Spiden AGDCB Research AGRecruitingType 1 Diabetes Mellitus | Type 1 Diabetes Mellitus With Hypoglycemia | Type 1 Diabetes Mellitus With HyperglycemiaSwitzerland
-
Instytut Diabetologii Sp. z o.o.National Center for Research and Development, Poland; Nalecz Institute of Biocybernetics...UnknownType 1 Diabetes Mellitus With Hyperglycemia | Type 1 Diabetes Mellitus With HypoglycaemiaPoland
Clinical Trials on Ethanol
-
Parc de Salut MarCompletedHealthy | Alcohol ConsumptionSpain
-
Virginia Commonwealth UniversityU.S. Department of JusticeRecruitingElectronic Cigarette UseUnited States
-
Yale UniversityVA Connecticut Healthcare SystemCompleted
-
Beth Israel Deaconess Medical CenterNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Completed
-
Virginia Commonwealth UniversityU.S. Department of JusticeCompleted
-
Merck Sharp & Dohme LLCCompleted
-
University of NebraskaWithdrawnShort Bowel Syndrome | Blood Stream InfectionsUnited States
-
National Institute of Diabetes and Digestive and...CompletedType 2 Diabetes, Insulin RequiringUnited States
-
OrfagenFDA Office of Orphan Products DevelopmentCompletedCongenital Venous MalformationUnited States, France
-
Indonesia UniversityNetherlands: Ministry of Health, Welfare and SportsCompleted